This study assessed the use of ribavirin monotherapy to enhance sustained virologic response in hepatitis C virus (HCV)-infected patients who achieved virologic response to interferon (IFN)-ribavirin combination therapy. Patients who had chronic HCV infection and prior relapse were retreated with IFN-ribavirin for 6 months. Patients with an end-of-treatment virologic response were assigned randomly to either stop use of both IFN and ribavirin or to continue use of ribavirin as monotherapy for an additional 6 months. HCV RNA became undetectable during treatment in 46 patients, who then entered the randomized trial. Sustained virologic response was observed in 13 of 26 patients who continued ribavirin monotherapy and in 15 of 20 patients who stopped use of both IFN and ribavirin (P, not significant). Sustained virologic response was significantly more common in patients with HCV genotype non-1 (75% vs. 56%) and in patients with a virus titer copies/mL (93% vs. 43%). The 6 ! 2 ϫ 10 results indicate that continuing ribavirin monotherapy after achieving a virologic response does not improve sustained virologic response.
rate in patients with chronic HCV infection. The present study was designed to test this hypothesis and was conducted with a group of patients who had virus relapse after treatment with IFN monotherapy.
Patients and Methods
Patients. All patients enrolled in the trial had documented chronic HCV infection established by the following criteria: a history of an elevation in serum alanine aminotransferase (ALT) level before initial treatment with IFN, anti-HCV positivity by second generation ELISA, and HCV RNA positivity by a sensitive polymerase chain reaction (PCR). Patients with any other cause of chronic hepatitis were excluded from study entry by appropriate serologic testing and histologic examination of liver tissue. All patients were negative for hepatitis B virus surface antigen, had negative or insignificant elevations in serum titers of antinuclear antibody and anti-smooth muscle antibody, and normal values for serum a-1-antitrypsin and ceruloplasmin. Patients with elevations in serum iron saturation or ferritin had liver tissue analyzed for iron content. All patients with significant stainable iron within the histologic specimen were excluded. Patients also were excluded from participation if they actively used injection drugs, regularly consumed alcohol, were human immunodeficiency virus positive, were pregnant, had chronic renal failure, or had received an organ transplant.
All patients had been treated previously with IFN-a and had responded to the prior treatment before experiencing a relapse, as assessed by one of the following 2 criteria: first, if HCV RNA had not been assessed by a quantitative or qualitative PCR during the previous course of therapy, the patient had to have normalization of serum ALT level during treatment, normal ALT level at the end of this treatment, and elevated serum ALT level after discontinuation of therapy. Second, if HCV RNA was assessed by PCR, this had to be negative within 2 weeks of completing the prior course of IFN and then become positive after discontinuation of therapy. The prior course of IFN was for 6-12 months' duration.
Study design. All patients were retreated initially with IFN-a2b (Schering-Plough) 3 times/week, plus ribavirin 1000-1200 mg/ day in 2 divided doses (Schering-Plough) for 6 months. The dose of IFN used for retreatment was similar to the one to which the patient had responded during the previous course of therapy. For example, if the patient had been treated with 3 or 5 million units (mU) of IFN-a-2b, the same agent at the same dose was used for retreatment. If the patient had been treated with 3 or 6 mU of IFN-a-2a (Hoffmann-Roche), 3 or 5 mU of IFN-a-2b was used for retreatment. Likewise, if the prior treatment used 9 or 15 mg of IFN-a-con-1 (Amgen), 3 or 5 mU of IFN-a-2b was used for retreatment.
All patients who achieved a virologic response and had no HCV RNA detected after 6 months of retreatment with IFN-a-2b plus ribavirin were assigned randomly to 1 of 2 groups. The first group stopped use of both drugs. The second group stopped use of IFN but continued ribavirin for an additional 6 months as monotherapy. All patients were followed up for 18 months in total: 12 months after discontinuation of both IFN and ribavirin or 6 months after discontinuation of ribavirin monotherapy.
Laboratory studies and liver histology. We monitored serum ALT levels, total white blood cell (WBC) counts, absolute polymorphonuclear lymphocyte (PMNL) counts, hemoglobin levels, and platelet counts at baseline and at monthly intervals throughout the study. HCV RNA was determined by the National Genetics Institute (Foster City, CA) by a sensitive PCR at baseline and at 3-month intervals throughout the study. The lower limit for detection of HCV RNA by this assay was 100 copies/mL. HCV genotype was determined by InnoLipa assay [8] . The genotype was assessed on the baseline sample by National Genetics Institute.
Liver biopsies were performed for all patients within 1 year of entering this study. If the biopsy was done before the initial course of IFN but within 12 months of enrollment in the present study, the biopsy was not repeated. Each liver biopsy specimen was reviewed in a blinded fashion by a single pathologist (M.J.C.) and was assigned a numeric score according to the histologic activity index of Knodell et al. [9] .
Dose modifications. The IFN dose was reduced if values for WBC, PMNL, or platelet counts declined to 1000, 500, or 50,000 cells/mL, respectively. For patients receiving 5 mU of IFN, the dose was reduced to 3 mU. For patients receiving 3 mU, the dose was reduced to 1.5 mU. The dosing frequency remained 3 times/ week. Patients who could not tolerate an IFN dose of 1.5 mU 3 times/week were dropped from the study. Patients who required a reduction in IFN dosage were maintained on this lower dose throughout the rest of the study.
The starting dose of ribavirin was 1200 mg daily (600 mg twice daily) for patients who weighed 170 kg. Patients who weighed !70 kg were treated with 1000 mg of ribavirin daily (400 mg in the morning and 600 mg in the afternoon). The ribavirin dose was reduced to 600 mg daily (200 mg in the morning and 400 mg in the afternoon) for patients in whom hemoglobin levels declined 13 g/dL from baseline or if hemoglobin levels fell below 10 g/dL. Patients who required a reduction in ribavirin dosage were maintained on this lower dose throughout the remainder of the study.
Statistical analysis. Values for age, serum ALT level, serum HCV RNA titer, and histologic activity index were reported as . Values for serum HCV RNA level were first converted mean ‫ע‬ SE to a log scale. Analysis of variance, the Mann-Whitney U test, or the log-rank test was used, as appropriate, to determine whether any observed differences in these parameters between the 2 treatment groups were significant. We used x 2 analysis to determine whether the numbers of patients who achieved biochemical or virologic response at various time intervals during and after treatment in the 2 groups were significantly different from one another.
Results
Response to IFN-ribavirin retreatment. In all, 62 patients were enrolled in the study (mean age, years). Of the 43.5 ‫ע‬ 1.2 participants, 60% were men, 73% were white, 21% were black, and 4 were Hispanic or Asian. The documentation of relapse was based on virologic criteria for 55 patients (88%). The mean serum ALT level and log HCV RNA titer before retreatment were IU/L and copies/mL, respec-133.3 ‫ע‬ 13. 6 6.24 ‫ע‬ 0.10 tively. Other findings were that 70% of the patients had HCV genotype 1, the mean Knodell score was , and 11% 5.5 ‫ע‬ 0.3 of the patients had cirrhosis.
Of 62 patients, 46 (74%) had no detectable HCV RNA after 6 months of retreatment with IFN-ribavirin. Eight (13%) did not respond to retreatment, and another 8 discontinued the study before completing 6 months of treatment. Two of the latter had become HCV RNA negative, but both had relapses within 3 months of discontinuing treatment. demographic and baseline laboratory and histologic data, by response to retreatment. The ability to achieve a virologic response to IFN-ribavirin retreatment was reduced significantly in the black population ( ) and in patients with a non-1 P ! .01 HCV genotype ( ). P ! .01 Effects of continuing ribavirin use as monotherapy. All 46 patients who were HCV RNA negative after completing 6 months of IFN and ribavirin therapy were randomized into the study and either stopped therapy or continued treatment with ribavirin monotherapy. Patients in each group were well matched for all demographic, biochemical, virologic, and histologic factors (table 2) . A sustained virologic response was observed in 13 of 26 patients randomized to continue use of ribavirin alone for an additional 6 months. For patients who stopped use of both IFN and ribavirin, sustained virologic response was observed for 15 of 20 patients. This difference was not significant ( ). Continuing to use ribavirin for an P p .156 additional 6 months did not delay the time of virologic relapse, nor did it reduce the HCV RNA titer during months 6-12 after relapse (figure 1). Table 3 lists various factors that may contribute to sustained virologic response. The ability to achieve a sustained virologic response versus relapse was significantly greater in patients with an HCV RNA titer !2 million copies/mL ( ) and in pa-P ! .01 tients without cirrhosis ( ). Only 3 of 7 patients with P p .05 cirrhosis responded to retreatment, and none achieved a sustained virologic response. Nine (75%) of 12 patients infected with a non-1 HCV genotype achieved a sustained virologic response, compared with only 56% of patients with HCV genotype 1. However, given the small number of patients infected with the non-1 HCV genotype, this difference was not significant. In all, 92% (11/12) of patients who became HCV RNA negative within 1 month of starting retreatment achieved a sustained virologic response.
Adverse events. Eight patients discontinued the study before completing 6 months of IFN-ribavirin therapy (table 1) . Two had become HCV RNA negative before dropping out but were considered to be nonresponders in an intention-to-treat analysis. The primary reasons for discontinuation were generalized nonspecific symptoms that included fatigue, mylagias, arthralgias, and nausea, which occurred in 6 of 8 patients. One patient developed thrombocytopenia, and another developed anemia. Figure 2 illustrates the effect of treatment on serum hemoglobin level. The mean decline in hemoglobin level during treatment with IFN-ribavirin was 2.5 g/dL. The greatest single decline was 6.3 g/dL. As expected, hemoglobin gradually returned to the pretreatment baseline level after IFN-ribavirin therapy was discontinued. However, even among the patients who continued to receive ribavirin monotherapy, hemoglobin returned to baseline levels over the same time interval.
Discussion
Ribavirin is both an antiviral and immune modulatory agent [10] [11] [12] [13] . Ribavirin exerts this effect by inhibiting inosine 5 -monophosphate dehydrogenase (IMPDH), an enzyme that regulates intracellular nucleic acid synthesis [10] . Inhibition of IMPDH by ribavirin reduces intracellular guanine and leads to a reduction in both DNA and RNA synthesis. Previous studies have demonstrated that use of ribavirin in patients with chronic HCV infection has little effect on the serum level of HCV RNA but leads to a significant reduction in serum ALT level [14, 15] . In contrast, use of ribavirin plus IFN enhances virologic responses and reduces relapses in patients with chronic HCV infection [1] [2] [3] [4] [5] . On the basis of these observations, we hypothesized that continued treatment with ribavirin monotherapy in patients in whom HCV RNA became undetectable after a course of IFN-ribavirin might lead to a further reduction in relapse and thereby improve sustained virologic response.
The present study was performed with patients who relapsed after a course of IFN monotherapy. A previous study showed that ∼80% of such patients will have undetectable HCV RNA when retreated for just 6 months with IFN and ribavirin combination therapy; sustained virologic response was achieved in ∼50% of these patients [6] . We chose this population for which to test our hypothesis both because of its high response to IFNribavirin combination therapy and because of the significant rate of relapse observed after discontinuation of therapy. Unfortunately, continuing ribavirin as monotherapy after these patients had responded to IFN and ribavirin did not lead to a further increase in sustained virologic response. This was observed for 13 of 26 patients who continued to receive ribavirin monotherapy and for 15 of 20 who discontinued both IFN and ribavirin.
It is now widely accepted that patients infected with HCV genotype 1 require 48 weeks of IFN and ribavirin therapy to have the greatest chance of achieving a sustained virologic response [3, 4] . In contrast, in the study by Davis et al. [6] and in the present study, patients who relapsed after IFN monotherapy were retreated for only 6 months with IFN and ribavirin. This may explain the relatively low rate of sustained virologic response for patients with HCV genotype 1 observed in the present study, 56% versus 75% for genotype non-1 (table  3) . Of note, the percentages of patients with HCV genotype 1 were similar in both groups after randomization. As a result, differences in HCV genotype cannot explain the negative results of the present study.
Previous studies have demonstrated that the prognostic factors associated with a sustained virologic response include being infected with HCV genotypes 2 or 3, a virus titer of !2 million copies/mL, not having cirrhosis, being female, and not being black [3-5, 16, 17] . In the present study, race and HCV genotype were prognostic factors for becoming HCV RNA negative during retreatment (table 1) , and virus titer and cirrhosis were prognostic factors for sustaining this response (table 3) .
One of the major side effects of ribavirin is hemolytic anemia [14, 18] . Indeed, the mean decline in serum hemoglobin level in this study was 2.5 g/dL; the greatest decline observed in any patient was 6.3 g/dL (figure 2). Discontinuation of both IFN and ribavirin resulted in a rapid increase in serum hemoglobin level to the pretreatment baseline level. Similarly, among patients who continued to receive ribavirin monotherapy, there was also a rapid increase in serum hemoglobin level to the pretreatment baseline level after the discontinuation of IFN. This observation strongly suggests that IFN-induced bone marrow suppression is responsible, at least in part, for the anemia observed in patients during combination therapy and suggests that the use of erythropoietin, as advocated by some [19] , may, in fact, be effective in combating the anemia induced during combination therapy.
Combination IFN and ribavirin therapy is currently the most effective treatment for patients with chronic HCV infection. However, 150% of patients will achieve a sustained virologic response after treatment with pegylated IFN plus ribavirin [20] , and this will no doubt become the new standard of care for patients with chronic HCV infection in the near future. Unfortunately, a significant number of patients will continue to relapse after treatment with combination therapy and will require innovative treatment approaches. One possible option will be treatment for longer periods. Indeed, prolonged therapy has been effective in achieving a sustained virologic response in some patients who had relapses after IFN monotherapy [21] [22] [23] . However, the present study clearly shows that continued ribavirin monotherapy in such patients will not improve sustained virologic response.
